STOCK TITAN

Evotec SE American Depositary Shares - EVO STOCK NEWS

Welcome to our dedicated page for Evotec SE American Depositary Shares news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE American Depositary Shares stock.

Evotec SE, headquartered in Hamburg, Germany, is a leading global drug discovery and development company. Specializing in providing comprehensive solutions to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations, Evotec is renowned for its extensive capabilities in therapeutic areas such as central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

Evotec’s core business is divided into two main segments: Shared R&D and Just-Evotec Biologics. The Shared R&D segment, making up approximately 80% of the company's sales, offers drug discovery and manufacturing services on a fee-for-service basis. It also engages in integrated drug discovery collaborations leveraging proprietary, internally-developed assets. Just-Evotec Biologics, accounting for about 20% of sales, provides contract development and manufacturing (CDMO) services for biologics.

With a workforce of over 5,000 employees, Evotec operates 18 production sites mainly across Europe and the United States. In recent years, the company has made significant strides in forming strategic alliances and collaborations, such as the recent partnership with Claris Ventures and Variant Bio, aimed at accelerating the development of innovative therapeutics.

Evotec’s multimodal platform combines cutting-edge technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. The company’s integrated R&D network includes partnerships with all Top 20 Pharma companies and over 800 biotech companies, academic institutions, and other healthcare stakeholders. This robust network facilitates the co-creation of a world-leading pipeline of over 200 proprietary and co-owned R&D projects, ranging from early discovery to clinical development.

Recent achievements by Evotec include the successful Clinical Trial Application (CTA) for IAMA Therapeutics’ lead program IAMA-6 and the strategic collaboration with Janssen for immune-based therapies. Additionally, Evotec has expanded its relationship with Bristol Myers Squibb in neurodegeneration and targeted protein degradation.

Financially, Evotec has demonstrated resilience despite macroeconomic challenges and a substantial cyber-attack in 2023. The company reported a 4% increase in revenues, reaching €781.4 million in 2023, driven by new collaborations and the strong performance of Just-Evotec Biologics.

As of 2024, Evotec continues to focus on sustainable and profitable growth, optimizing its operations to meet evolving market demands. The company is committed to advancing its mission of discovering and developing effective therapeutics that address unmet medical needs globally.

News
Rhea-AI Summary
Evotec SE (EVT) announces CEO Dr. Werner Lanthaler's resignation for personal reasons. Dr. Mario Polywka to serve as interim CEO. The company confirms its 2023 guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.81%
Tags
none
-
Rhea-AI Summary
Evotec SE (EVT) has received a US$ 2.5 million grant from the Bill & Melinda Gates Foundation for its teratogenicity platform and joins the foundation's Global Health Discovery Collaboratory. The grant provides GHDC members access to Evotec's high-throughput teratogenicity platform at no extra cost, enabling cost-effective de-risking of drug candidates early in the discovery process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
Evotec SE (EVT) partners with Charité Universitätsmedizin Berlin to create a molecular patient database for ANCA-associated vasculitis, a group of rare autoimmune diseases. The partnership aims to improve disease understanding and treatment through the analysis of patient material using Evotec's PanOmics platform. Charité will collect biosamples, and Evotec will leverage its M.L.-powered platform to translate research into precision therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.29%
Tags
partnership
Rhea-AI Summary
Evotec SE (EVT) announced that its license partner, Zhejiang Jingxin Pharmaceutical Co., Ltd, has received approval from the Chinese National Medical Products Administration for the novel insomnia treatment EVT201, also known as Dimdazenil in China. This treatment is a partial positive allosteric modulator of the GABAA receptor with high affinity and moderate efficacy. Evotec will receive double-digit royalties of net sales as well as milestones based on commercial success and further sub-licensing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
none
-
Rhea-AI Summary
Evotec SE (EVT) Presents Precision Medicine Capabilities at Capital Markets Day, Highlighting PanOmics, iPSC, and A.I./M.L. Platforms. The company confirms Action Plan 2025 goals and updates progress, showcasing investments of ~€450m into PanOmics and iPSCs, resulting in cumulated revenues of >€1bn and creating a milestone pool of >€15bn. The event emphasizes the introduction of a differentiated offering to shape untapped markets, fostering double-digit growth, and discusses the next big developments in the co-owned pipeline with insights to novel first-in-class targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Summary
Evotec SE (Frankfurt Stock Exchange: EVT, NASDAQ:EVO) announced 14% revenue growth to € 580.1 m in the first nine months of 2023, driven by strong demand and pipeline progress. Despite a cyber-incident costing € 43.9 m, adjusted Group EBITDA increased by 13% to € 50.2 m. The company also reported multiple new drug discovery agreements, co-owned pipeline progress, and a corporate update on its environmental initiatives. The business outlook for full-year 2023 and mid-term goals for 2025 were confirmed, with a focus on revenue growth and emission reduction targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
none
Rhea-AI Summary
Evotec SE and Dewpoint Therapeutics have announced a strategic R&D collaboration to advance Dewpoint's oncology pipeline programs using Evotec's data-driven platform. The partnership aims to de-risk and accelerate pre-clinical development candidates to first-in-human clinical studies. Evotec will facilitate the rapid development of Dewpoint's assets using its INDiGO platform. The agreement includes a risk-sharing arrangement and milestone and royalty payments based on program success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
partnership
-
Rhea-AI Summary
Evotec SE announces new partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund to advance drug discovery and create new therapeutics companies in Singapore.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
-
Rhea-AI Summary
Evotec partners with LabCentral, BioLabs, and MBC BioLabs to provide access to its R&D platform for biotech startups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
Rhea-AI Summary
Evotec and Novo Nordisk announce LAB eN², a translational drug discovery accelerator focused on cardiometabolic diseases. Four academic institutions, including Harvard University and Mass General Brigham, have already signed on to participate. LAB eN² aims to accelerate the translation of academic ideas into therapeutic product candidates. It will provide funding, scientific expertise, and technology to advance concepts through pre-clinical proof of concept. Successful candidates may be selected for further investment and development by Novo Nordisk. The prevalence of cardiometabolic diseases is increasing, creating a significant need for new therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none

FAQ

What is the current stock price of Evotec SE American Depositary Shares (EVO)?

The current stock price of Evotec SE American Depositary Shares (EVO) is $4.49 as of November 22, 2024.

What is the market cap of Evotec SE American Depositary Shares (EVO)?

The market cap of Evotec SE American Depositary Shares (EVO) is approximately 1.6B.

What is Evotec SE?

Evotec SE is a global drug discovery and development company headquartered in Hamburg, Germany. It provides comprehensive solutions in drug discovery and manufacturing to pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations.

What are Evotec's main business segments?

Evotec's business is divided into Shared R&D, which offers drug discovery and manufacturing services, and Just-Evotec Biologics, which provides CDMO services for biologics.

Who are Evotec's partners?

Evotec collaborates with all Top 20 Pharma companies, over 800 biotech companies, academic institutions, and other healthcare stakeholders.

What recent collaborations has Evotec entered into?

Recent collaborations include partnerships with Claris Ventures to accelerate programs into the clinic and with Variant Bio to develop treatments for fibrotic diseases.

How many employees does Evotec have?

Evotec employs over 5,000 people across 18 production sites in Europe and the United States.

What are Evotec's key therapeutic areas?

Evotec focuses on central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health.

What financial performance did Evotec report in 2023?

Evotec reported a 4% increase in revenues, reaching €781.4 million in 2023, despite challenging economic conditions and a cyber-attack.

What are the future goals of Evotec?

Evotec aims to focus on sustainable and profitable growth, optimizing its operations and continuing to advance its mission of developing effective therapeutics.

What is Just-Evotec Biologics?

Just-Evotec Biologics is a segment of Evotec that offers contract development and manufacturing services for biologics.

What makes Evotec's platform unique?

Evotec’s multimodal platform combines innovative technologies, data, and scientific expertise to drive the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec SE American Depositary Shares

OTC:EVO

EVO Rankings

EVO Stock Data

1.58B
354.61M
2.34%
0.06%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Hamburg